by Team Small News | Mar 25, 2025 | Pfizer, Pharma
The article focuses on the latest development in the biopharma industry, specifically the exit of Pfizer from the market. According to the author, Andy Smith, the high price of treatments is the primary reason for Pfizer’s departure. This comes as a surprise, as... by Team Small News | Mar 24, 2025 | Pfizer, Pharma
Chinese Vice Premier He Lifeng recently met with the heads of several multinational corporations, including Apple, Pfizer, Cargill, MasterCard, and Eli Lilly, to reassure them of China’s potential for business growth and investment. The meetings were seen as a... by Team Small News | Mar 23, 2025 | Pfizer, Pharma
Mikael Dolsten, a renowned pharmaceutical expert, has joined Immunai as a strategic advisor, bringing with him over 25 years of experience in leadership roles at major pharmaceutical companies, including Pfizer, Wyeth, Boehringer Ingelheim, and AstraZeneca. During his... by Team Small News | Mar 22, 2025 | Pfizer, Pharma
Pfizer has received a nod from the Central Drugs Standard Control Organization (CDSCO) panel to conduct a clinical trial of its anticancer drug, Disitamab vedotin, in India. The panel’s approval will enable the company to proceed with the study, which is... by Team Small News | Mar 22, 2025 | Pfizer, Pharma
The article highlights three companies, Pfizer (PFE), Spire (SR), and TriCo Bancshares (TCBK), that have a long history of paying dividends and consistently increasing them, making them attractive to income-focused investors. Pfizer, for instance, has raised its... by Team Small News | Mar 19, 2025 | Pfizer, Pharma
The Urinary Tract Infection (UTI) market is expected to reach a market size of USD 11.64 billion by 2033, growing at a CAGR of 2.74% from 2025 to 2033. The primary drivers of the market are the increasing incidence of UTIs, growing awareness of the importance of...